Takeda San Diego, Inc., 10410 Science Center Drive, San Diego, California 92121, United States.
J Med Chem. 2011 Jan 27;54(2):510-24. doi: 10.1021/jm101016w. Epub 2010 Dec 27.
The discovery of two classes of heterocyclic dipeptidyl peptidase IV (DPP-4) inhibitors, pyrimidinones and pyrimidinediones, is described. After a single oral dose, these potent, selective, and noncovalent inhibitors provide sustained reduction of plasma DPP-4 activity and lowering of blood glucose in animal models of diabetes. Compounds 13a, 27b, and 27j were selected for development.
描述了两类杂环二肽基肽酶 4(DPP-4)抑制剂,即嘧啶酮和嘧啶二酮的发现。这些强效、选择性和非共价抑制剂在糖尿病动物模型中单次口服后,可持续降低血浆 DPP-4 活性和血糖。化合物 13a、27b 和 27j 被选为开发对象。